Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand ...

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.

Gilead Sciences, Inc. GILD announced that the FDA has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus (HDV) infection. The approval makes ...

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX ...

The biotechnology and drug manufacturing market continues to give investors a hit-and-miss. Bears are betting heavily against Hims and Hers (HIMS), holding a short interest of 28.31%. On May 21, Hims ...

A new experiment is seeking to validate whether living cancer samples can be prepared, operated, monitored, and recovered ...